{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-077584","form_type":"8-K","ticker":"CTSO","cik":"0001175151","company_name":"Cytosorbents Corp","filed_at":"2026-06-25T13:26:59+00:00","discovered_at":"2026-06-25T13:28:00.195492+00:00","generated_at":"2026-06-25T13:28:11.852694+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CytoSorbents schedules two FDA pre-submission meetings for ticagrelor and DOAC programs in August 2026","bullets":["Two pre-submission meetings with FDA scheduled for August 2026.","Meetings will cover CytoSorbents' ticagrelor and DOAC programs.","Announcement made at 2026 Life Sciences Forum; no financial impact disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-077584","json":"https://secwatch.observer/filing/0001104659-26-077584.json","markdown":"https://secwatch.observer/filing/0001104659-26-077584.md","text":"https://secwatch.observer/filing/0001104659-26-077584.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175151/000110465926077584/0001104659-26-077584-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175151/000110465926077584/tm2618977d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T13:28:11.852694+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}